Literature DB >> 30076178

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Emanuela Messa1,2, Daniela Gioia2, Elisa Masiera2, Anna Castiglione3, Manuela Ceccarelli3, Flavia Salvi4,2, Paolo Danise5,2, Alessandro Sanna6,2, Bernardino Allione7,2, Enrico Balleari8,2, Antonella Poloni9,2, Giovanni Cametti10,2, Dario Ferrero11,2, Rodolfo Tassara12,2, Carlo Finelli13,2, Margherita Bonferroni14,2, Pellegrino Musto15,2, Giuseppe Saglio16,2, Alessandro Levis2, Valeria Santini17,2.   

Abstract

Entities:  

Year:  2018        PMID： 30076178      PMCID： PMC6312022          DOI： 10.3324/haematol.2017.183590

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Peter L Greenberg; Richard M Stone; Aref Al-Kali; Stefan K Barta; Rafael Bejar; John M Bennett; Hetty Carraway; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Ruth Horsfall; Robert A Johnson; Mark Juckett; Virginia M Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Paul J Shami; Brady L Stein; Alison R Walker; Peter Westervelt; Amer Zeidan; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2017-01       Impact factor: 11.908

2.  Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.

Authors:  Pellegrino Musto; Oreste Villani; Maria Carmen Martorelli; Giuseppe Pietrantuono; Roberto Guariglia; Giovanna Mansueto; Fiorella D'Auria; Vitina Grieco; Gabriella Bianchino; Anna Sparano; Antonia Zonno; Rosa Lerose; Grazia Sanpaolo; Antonietta Falcone
Journal:  Leuk Res       Date:  2009-11-20       Impact factor: 3.156

3.  Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

Authors:  V Santini; P E Alessandrino; E Angelucci; G Barosi; A Billio; M Di Maio; C Finelli; F Locatelli; M Marchetti; E Morra; P Musto; G Visani; S Tura
Journal:  Leuk Res       Date:  2010-02-11       Impact factor: 3.156

4.  American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Authors:  J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Mark R Somerfield; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

5.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

Authors:  Sophie Park; Charikleia Kelaidi; Rosa Sapena; Dominique Vassilieff; Odile Beyne-Rauzy; Valérie Coiteux; Norbert Vey; Christophe Ravoet; Stéphane Cheze; Christian Rose; Laurence Legros; Aspasia Stamatoullas; Martine Escoffre-Barbe; Agnès Guerci; Marie-Pierre Chaury; Pierre Fenaux; François Dreyfus
Journal:  Leuk Res       Date:  2010-06-26       Impact factor: 3.156

7.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

8.  A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

Authors:  U Platzbecker; A Symeonidis; E N Oliva; J S Goede; M Delforge; J Mayer; B Slama; S Badre; E Gasal; B Mehta; J Franklin
Journal:  Leukemia       Date:  2017-06-19       Impact factor: 11.528

9.  A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

Authors:  Pierre Fenaux; Valeria Santini; Maria Antonietta Aloe Spiriti; Aristoteles Giagounidis; Rudolf Schlag; Atanas Radinoff; Liana Gercheva-Kyuchukova; Achilles Anagnostopoulos; Esther Natalie Oliva; Argiris Symeonidis; Mathilde Hunault Berger; Katharina S Götze; Anna Potamianou; Hari Haralampiev; Robert Wapenaar; Iordanis Milionis; Uwe Platzbecker
Journal:  Leukemia       Date:  2018-03-30       Impact factor: 11.528

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more
  3 in total

1.  Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.

Authors:  Saroj Hattakitpanitchakul; Sirorat Kobbuaklee; Kitsada Wudhikarn; Chantana Polprasert
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

2.  Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Authors:  Enrico Balleari; Rosa Angela Filiberti; Chiara Salvetti; Bernardino Allione; Emanuele Angelucci; Marco Bruzzone; Tullio Calzamiglia; Marina Cavaliere; Maurizio Cavalleri; Daniela Cilloni; Marino Clavio; Elena Crisà; Anna Da Col; Paolo Danise; Federica Pilo; Dario Ferrero; Carlo Finelli; Daniela Gioia; Roberto Massimo Lemoli; Elisa Masiera; Emanuela Messa; Maurizio Miglino; Pellegrino Musto; Esther Natalie Oliva; Antonella Poloni; Flavia Salvi; Alessandro Sanna; Marco Scudeletti; Rodolfo Tassara; Valeria Santini
Journal:  Cancer Med       Date:  2019-10-27       Impact factor: 4.452

Review 3.  Practice review: Evidence-based and effective management of anaemia in palliative care patients.

Authors:  Karen Neoh; Andrew Page; Nicolas Chin-Yee; Carolyn Doree; Michael I Bennett
Journal:  Palliat Med       Date:  2022-03-24       Impact factor: 5.713
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.